- Home
- ERIE vs BIIB Comparison
ERIE vs BIIB Comparison
Compare ERIE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERIE
- BIIB
- Stock Information
- Founded
- ERIE 1925
- BIIB 1978
- Country
- ERIE United States
- BIIB United States
- Employees
- ERIE N/A
- BIIB N/A
- Industry
- ERIE Specialty Insurers
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- ERIE Finance
- BIIB Health Care
- Exchange
- ERIE Nasdaq
- BIIB Nasdaq
- Market Cap
- ERIE 19.2B
- BIIB 18.7B
- IPO Year
- ERIE 1995
- BIIB 1991
- Fundamental
- Price
- ERIE $354.38
- BIIB $132.22
- Analyst Decision
- ERIE
- BIIB Buy
- Analyst Count
- ERIE 0
- BIIB 27
- Target Price
- ERIE N/A
- BIIB $188.09
- AVG Volume (30 Days)
- ERIE 130.3K
- BIIB 1.4M
- Earning Date
- ERIE 08-07-2025
- BIIB 10-29-2025
- Dividend Yield
- ERIE 1.54%
- BIIB N/A
- EPS Growth
- ERIE 17.80
- BIIB 31.67
- EPS
- ERIE 11.95
- BIIB 10.45
- Revenue
- ERIE $3,973,472,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- ERIE $10.96
- BIIB $2.00
- Revenue Next Year
- ERIE $8.12
- BIIB N/A
- P/E Ratio
- ERIE $29.66
- BIIB $12.65
- Revenue Growth
- ERIE 12.00
- BIIB 3.36
- 52 Week Low
- ERIE $332.34
- BIIB $110.04
- 52 Week High
- ERIE $547.00
- BIIB $206.70
- Technical
- Relative Strength Index (RSI)
- ERIE 46.76
- BIIB 46.86
- Support Level
- ERIE $348.71
- BIIB $135.22
- Resistance Level
- ERIE $368.80
- BIIB $138.50
- Average True Range (ATR)
- ERIE 5.99
- BIIB 3.37
- MACD
- ERIE -1.54
- BIIB -0.47
- Stochastic Oscillator
- ERIE 24.93
- BIIB 28.22
About ERIE Erie Indemnity Company
Erie Indemnity Co mainly performs services on behalf of the Erie Insurance Exchange relating to sales, underwriting, and issuance of policies. Erie Indemnity's results are tied to the performance of the Insurance Exchange, which principally provides automobile and homeowners insurance for individuals, along with multiperil, workers' compensation, and commercial automobile insurance for its commercial clients. The company operates exclusively in the United States.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.